TSI Gains Patent for Promilin

MISSOULA, Mont.—TSI Health Sciences Inc. received a new U.S. patent (No. 7,338,675), “Fenugreek seed bio-active compositions and methods for extracting same,” for its Promilin® ingredient. A key provision of the patent involves the separation of bioactives of 4-hydroxyisoleucine from fenugreek; the unique composition works synergistically with insulin or independently to stimulate glucose uptake and transport.

“The award of the patent is significant, covering both composition and application,” said Sandy Chien, TSI Health Sciences. “It reaffirms our commitment to investing in innovative ingredients and intellectual property with a long-term vision for the market and support of our clients. This patent adds important depth to TSI’s intellectual property portfolio and allows us to work with our clients to develop innovative, efficacious products based on Promilin and our patented technology.”